<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04603495</url>
  </required_header>
  <id_info>
    <org_study_id>0610-04</org_study_id>
    <secondary_id>2020-001989-10</secondary_id>
    <nct_id>NCT04603495</nct_id>
  </id_info>
  <brief_title>Study of CPI-0610 in Myelofibrosis (MF)</brief_title>
  <acronym>MANIFEST-2</acronym>
  <official_title>A Phase 3, Randomized, Double-blind, Active-Control Study of CPI-0610 and Ruxolitinib vs. Placebo and Ruxolitinib in JAKi Treatment Naive MF Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Constellation Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Constellation Pharmaceuticals</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 3, randomized, blinded study comparing CPI-0610 and ruxolitinib with placebo and&#xD;
      ruxolitinib in myelofibrosis (MF) patients that have not been exposed previously to Janus&#xD;
      kinase inhibitors (JAKi). CPI-0610 is a small molecule inhibitor of bromodomain and&#xD;
      extra-terminal (BET) proteins. Evidence suggests that inhibition of both BET and JAK pathways&#xD;
      can result in synergistic reduction of disease and overall improvement in the prognosis of&#xD;
      MF.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 19, 2020</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>This study has a double-blind design in which patients and investigators are blinded to study drug; study drugs will be packaged identically. All patients will be randomly assigned to either treatment group in a 1:1 ratio. The blind should only be broken in the case of emergency.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Splenic response at Week 24</measure>
    <time_frame>24 weeks of treatment</time_frame>
    <description>The primary endpoint of the study is splenic response, defined as a ≥35% reduction from baseline in spleen volume as measured by magnetic resonance imaging (MRI) or computerized tomography (CT), at Week 24.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total Symptom Score response at Week 24</measure>
    <time_frame>24 weeks of treatment</time_frame>
    <description>The key secondary endpoint of the study is Total Symptom Score response, defined as a ≥50% decrease from baseline in Total Symptom Score as measured by the Myelofibrosis Symptom Assessment Form v4.0, at Week 24. A higher Total Symptom Score indicates a higher disease burden and thus a worse outcome.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">310</enrollment>
  <condition>Myelofibrosis</condition>
  <condition>Primary Myelofibrosis</condition>
  <condition>Post-polycythemia Vera Myelofibrosis</condition>
  <condition>Post-essential Thrombocythemia Myelofibrosis</condition>
  <arm_group>
    <arm_group_label>CPI-0610 + ruxolitinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CPI-0610 monohydrate tablets + ruxolitinib phosphate tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + ruxolitinib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Matching placebo tablets + ruxolitinib phosphate tablets</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CPI-0610</intervention_name>
    <description>Double-blind treatment (CPI-0610 or matching placebo) will be administered daily for 14 consecutive days followed by a 7-day break, which is considered 1 cycle of treatment (1 cycle = 21 days).&#xD;
CPI-0610 is a small molecule inhibitor of BET proteins with a novel mechanism of action and potential for disease-modifying effects in MF.</description>
    <arm_group_label>CPI-0610 + ruxolitinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ruxolitinib</intervention_name>
    <description>Ruxolitinib is a JAK inhibitor and a current, approved treatment option for MF.</description>
    <arm_group_label>CPI-0610 + ruxolitinib</arm_group_label>
    <arm_group_label>Placebo + ruxolitinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablets are designed to match CPI-0610 tablets. Each placebo tablet contains no active pharmaceutical ingredient and is visibly identical to experimental drug in size, shape, and packaging. Placebo dosing follows the same dosing conventions as CPI-0610.</description>
    <arm_group_label>Placebo + ruxolitinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged ≥ 18 years&#xD;
&#xD;
          -  Confirmed diagnosis of myelofibrosis (primary, post-polycythemia vera, or post&#xD;
             essential thrombocythemia)&#xD;
&#xD;
          -  Adequate hematologic, renal, and hepatic function&#xD;
&#xD;
          -  Have at least 2 symptoms with an average score ≥ 3 or an average total score of ≥ 10&#xD;
             over the 7-day period prior to randomization using the MFSAF v4.0&#xD;
&#xD;
          -  Prognostic risk-factor score of Intermediate-1 or higher per Dynamic International&#xD;
             Prognostic Scoring System (DIPSS) scoring system&#xD;
&#xD;
          -  Spleen volume of ≥ 450 cm^3&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Splenectomy or splenic irradiation in the previous 6 months&#xD;
&#xD;
          -  Chronic or active conditions and/or concomitant medication use that would prohibit&#xD;
             treatment&#xD;
&#xD;
          -  Had prior treatment with any JAKi or BET inhibitor for treatment of a&#xD;
             myeloproliferative neoplasm&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Debbie Johnson</last_name>
    <phone>617-714-0531</phone>
    <email>debbie.johnson@constellationpharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>UC San Diego Moores Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kimberly Aguilar</last_name>
      <phone>858-534-5201</phone>
      <email>K1aguilar@health.ucsd.edu</email>
    </contact>
    <investigator>
      <last_name>Catriona Jamieson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>USC/Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Duran</last_name>
      <phone>323-865-0371</phone>
      <email>duran_c@med.usc.edu</email>
    </contact>
    <investigator>
      <last_name>Casey O'Connell</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCLA Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruck Habtemariam, MD</last_name>
      <phone>310-794-0242</phone>
      <email>bhabtemariam@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Gary Schiller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Decatur Memorial Hospital Cancer Care Center of Decatur/Cancer Care Specialists of IL</name>
      <address>
        <city>Decatur</city>
        <state>Illinois</state>
        <zip>62526</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James L Wade, MD</last_name>
      <phone>217-876-6600</phone>
      <email>jlwade3@sbcglobal.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Loyola University - Cardinal Bernardin Cancer Center</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Berg, DO</last_name>
      <phone>708-327-3180</phone>
      <email>Stephanie.Berg@lumc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Franciscan Health/Indiana blood and Marrow Transplantation</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46237</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melanie Coleman</last_name>
      <phone>317-528-7298</phone>
      <email>melanie.coleman@franciscanalliance.org</email>
    </contact>
    <investigator>
      <last_name>Luke Akard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Norton Cancer Institute, St. Matthews Campus</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Don A Stevens, MD</last_name>
      <phone>502-899-3366</phone>
      <email>HEME-NCIResearch@nortonhealthcare.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Michigan Medical Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Moshe Talpaz, MD</last_name>
      <phone>800-865-1125</phone>
      <email>canceranswerline@med.umich.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen T Oh, MD/PhD</last_name>
      <phone>314-362-0156</phone>
      <email>kdgordon@wustl.edu</email>
    </contact>
    <contact_backup>
      <phone>314-747-7960</phone>
      <email>nrgaudin@wustl.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Summit Medical Group - Cancer Center</name>
      <address>
        <city>Florham Park</city>
        <state>New Jersey</state>
        <zip>07932</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Mackenzie</last_name>
      <phone>973-436-1755</phone>
      <email>mmackenzie@summithealth.com</email>
    </contact>
    <investigator>
      <last_name>KarLeung Siu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mikaela Daugherty</last_name>
      <phone>212-241-8839</phone>
      <email>mikaela.dougherty@mssm.edu</email>
    </contact>
    <investigator>
      <last_name>Marina Kremyanskaya</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raajit K Rampal, MD, PhD</last_name>
      <phone>646-608-3746</phone>
      <email>rampalr@mskcc.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College- New York Presbyterian Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tania Curcio, NP</last_name>
      <phone>212-746-2571</phone>
      <email>tjc9003@med.cornell.edu</email>
    </contact>
    <investigator>
      <last_name>Joseph Scandura, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Taussig Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aaron Gerds, MD/MS</last_name>
      <phone>216-445-9840</phone>
      <email>TaussigResearch@ccf.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Srdan Vertovsek, MD, PhD</last_name>
      <phone>713-745-3429</phone>
      <email>sverstov@mdanderson.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mays Cancer Center at UT Health San Antonio MD Anderson</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Epp Goodwin</last_name>
      <phone>210-450-5798</phone>
      <email>goodwine@uthscsa.edu</email>
    </contact>
    <investigator>
      <last_name>Rubin Mesa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Icon Cancer Centre</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4101</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Adam Stoneley</last_name>
      <phone>+61 7 3737 4558</phone>
      <email>adam.stoneley@icon.team</email>
    </contact>
    <contact_backup>
      <phone>+61 4 0001 4100</phone>
    </contact_backup>
    <investigator>
      <last_name>Ian Irving</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chris Hoare</last_name>
      <phone>+61 08 7074 3290</phone>
      <email>Christine.Hoare@sa.gov.au</email>
    </contact>
    <investigator>
      <last_name>David Ross, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Monash Health</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Micheleine Uhe</last_name>
      <phone>+61 3 9594 4044</phone>
      <email>Micheleine.uhe@monashhealth.org</email>
    </contact>
    <investigator>
      <last_name>Jake Shortt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peninsula Private Hospital Clinical Trials Unit</name>
      <address>
        <city>Frankston</city>
        <state>Victoria</state>
        <zip>3199</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Coordinator</last_name>
      <phone>+61 3 9788 3647</phone>
      <email>ClinicalTrials.PPH@ramsayhealth.com.au</email>
    </contact>
    <investigator>
      <last_name>Patricia Walker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>USC Clinical Trials Centre Sunshine Coast Haematology and Oncology Clinic</name>
      <address>
        <city>Buderim</city>
        <zip>QLD 4556</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical trials team</last_name>
      <phone>07 5479 0000</phone>
      <email>ctconcology@usc.edu.au</email>
    </contact>
    <investigator>
      <last_name>Sorab Shavaksha</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>LKH - Universitätsklinikum Graz; Abteilung für Hämatologie</name>
      <address>
        <city>Graz</city>
        <zip>A-8036</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Albert Woelfler</last_name>
      <phone>+43316-385-81207</phone>
      <email>albert.woelfler@medunigraz.at</email>
    </contact>
    <investigator>
      <last_name>Albert Woelfler</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cliniques universitaires Saint-Luc</name>
      <address>
        <city>Brussel</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Delphine Roelandts</last_name>
      <phone>+32 764 18 09</phone>
      <email>delphine.roelandts@uclouvain.be</email>
    </contact>
    <investigator>
      <last_name>Violaine Havelange, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital de Jolimont</name>
      <address>
        <city>La Louvière</city>
        <zip>7100</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne-Catherine GERARD</last_name>
      <phone>+3264231992</phone>
      <email>anne-catherine.gerard@jolimont.be</email>
    </contact>
    <investigator>
      <last_name>Benjamin Bailly, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charlotte Tuerlinckx</last_name>
      <phone>+32 16 34 25 14</phone>
      <email>charlotte.tuerlinckx@uzleuven.be</email>
    </contact>
    <investigator>
      <last_name>Timothy Devos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tom Baker Cancer Centre</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nicole Dunse</last_name>
      <phone>403-521-3221</phone>
      <email>Nicole.dunse@albertahealthservices.ca</email>
    </contact>
    <investigator>
      <last_name>Sonia Cerquozzi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Alberta Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ovais Shaikh</last_name>
      <phone>+1 780-407-3365</phone>
      <email>ovais.shaikh@ahs.ca</email>
    </contact>
    <investigator>
      <last_name>Aniket Bankar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Center - Victoria Hospital</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5W9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Priyand Gajiwala</last_name>
      <phone>519-685-8500</phone>
      <phone_ext>75017</phone_ext>
      <email>Priyand.gajiwala@lhsc.on.ca</email>
    </contact>
    <investigator>
      <last_name>Selay Lam, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Center</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vikas Gupta, MD</last_name>
      <phone>416-946-4501</phone>
      <phone_ext>5178</phone_ext>
      <email>vikas.gupta@uhn.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jewish General Hospital</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chadi Zakaria, PhD</last_name>
    </contact>
    <contact_backup>
      <phone>514-340-8222</phone>
      <phone_ext>28326</phone_ext>
      <email>chadi.zakaria.ccomtl@ssss.gouv.qc.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Shireen Sirhan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Amiens Picardie</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marine Quint</last_name>
      <phone>+33 3 22 45 54 23</phone>
      <email>quint.marine@chu-amiens.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Pierre Marolleau</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Henri-Mondor</name>
      <address>
        <city>Créteil</city>
        <zip>94010 Cedex</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ludovic Cabanne, MD</last_name>
      <phone>01 49 81 20 58</phone>
      <email>ludovic.cabanne@hmn.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Lydia Roy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier</name>
      <address>
        <city>Le Mans</city>
        <zip>72000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kamel Laribi, MD</last_name>
      <phone>33(0)243434361</phone>
      <email>klaribi@ch-lemans.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital de la Conception</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maurine Duhayon</last_name>
      <phone>+33491382971</phone>
      <email>maurine.duhayon@ap-hm.fr</email>
    </contact>
    <investigator>
      <last_name>Regis Costello</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital l'Archet 1</name>
      <address>
        <city>Nice</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica LECHARDEUR</last_name>
      <phone>+33 (0)4 92 03 90 87</phone>
      <email>lechardeur.j@chu-nice.fr</email>
    </contact>
    <investigator>
      <last_name>Michael Loschi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU DE NIMES _Institut de Cancérologie du Gard</name>
      <address>
        <city>Nîmes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diane UMUHIRE</last_name>
      <phone>+33.4.66.68.35.28</phone>
      <email>diane.umuhire@chu-nimes.fr</email>
    </contact>
    <investigator>
      <last_name>Eric Jourdan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud Secteur 1G</name>
      <address>
        <city>Pierre-Bénite</city>
        <zip>69310</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aline Praire</last_name>
      <phone>33478862222</phone>
      <email>aline.praire@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Fiorenzo Barraco</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Pontchaillou - Service Hematologie</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Corinne Picouleau</last_name>
      <phone>33 2 99 28 96 33</phone>
      <email>Corinne.picouleau@chu-rennes.fr</email>
    </contact>
    <investigator>
      <last_name>Marc Bernard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie Lucien Neuwirth</name>
      <address>
        <city>Saint-Priest-en-Jarez</city>
        <zip>42271</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Coralie DURIEUX</last_name>
      <phone>04 77 91 74 85</phone>
      <email>Coralie.durieux@icloire.fr</email>
    </contact>
    <investigator>
      <last_name>Silvia M Bezsera, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Bretonneau</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincent Gaborit</last_name>
      <phone>02 47 47 80 64</phone>
      <email>V.GABORIT@chu-tours.fr</email>
    </contact>
    <investigator>
      <last_name>Antoine Machet, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chru Brabois</name>
      <address>
        <city>Vandœuvre-lès-Nancy</city>
        <zip>54500</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claire Simon</last_name>
      <phone>03.83.15.52.34</phone>
      <email>cl.simon@chru-nancy.fr</email>
    </contact>
    <investigator>
      <last_name>Dana Ranta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Szabolcs Szatmár Bereg Megyei Kórházak és Egyetemi Oktatókórház; Jósa András Oktatókórház, Hematológia</name>
      <address>
        <city>Nyiregyhaza</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zsolt Horváth</last_name>
      <phone>+3620-998-5123</phone>
      <email>horvathzsolt00@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Laszlo Rejto, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O.U. Policlinico S. Orsola-Malpighi</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesca Palandri, MD, PhD</last_name>
      <phone>+39 0512143044</phone>
      <email>francesca.palandri@unibo.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Amsterdam UMC</name>
      <address>
        <city>Amsterdam</city>
        <zip>1081</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tineke Kruijt</last_name>
      <phone>+31 020-4449265</phone>
      <email>j.kruijt@vumc.nl</email>
    </contact>
    <investigator>
      <last_name>Marielle Wondergem</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maastricht University Medical Center</name>
      <address>
        <city>Maastricht</city>
        <zip>6229 HX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Claudia Geesing</last_name>
      <phone>(31 43) 388-2901</phone>
      <email>research.hematologie@mumc.nl</email>
    </contact>
    <investigator>
      <last_name>Gwendolyn Van Gorkom</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pratia Onkologia Katowice</name>
      <address>
        <city>Katowice</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Jakubiec</last_name>
      <phone>723995182</phone>
      <email>anna.jakubiec@pratia.com</email>
    </contact>
    <investigator>
      <last_name>Sebastian Grosicki</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Pratia</name>
      <address>
        <city>Skorzewo</city>
        <zip>60-185</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roza Jerzewska</last_name>
      <phone>+48506 969 916</phone>
      <email>roza.jerzewska@pratia.com</email>
    </contact>
    <investigator>
      <last_name>Maciej Kazmierczak</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nasz Lekarz Przychodnie Medyczne</name>
      <address>
        <city>Toruń</city>
        <zip>87-100</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karolina Zielinska</last_name>
      <phone>+48 56 300 43 00</phone>
      <email>k.zielinska@naszlekarz.pl</email>
    </contact>
    <investigator>
      <last_name>Dominik Chraniuk, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ICO Girona - Hospital Universitari de Girona</name>
      <address>
        <city>Girona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna A Figueras</last_name>
      <phone>+34 972 22 58 28</phone>
      <email>angona.figueras@iconcologia.net</email>
    </contact>
    <investigator>
      <last_name>Anna Angona Figueras</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Fundación Jiménez Díaz</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arantxa G Raso</last_name>
      <phone>+34 91 550 48 00</phone>
      <email>argarciar@quironsalud.es</email>
    </contact>
    <contact_backup>
      <last_name>Belen V Vaquero</last_name>
      <phone>+34 91 550 48 00</phone>
      <email>belen.veldhuizen@quironsalud.es</email>
    </contact_backup>
    <investigator>
      <last_name>Raquel Mata Serna</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Navarra</name>
      <address>
        <city>Pamplona</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Asier Artazcoz</last_name>
      <phone>+34 848 42 84 28</phone>
      <email>asier.artazcoz.calvo@navarra.es</email>
    </contact>
    <investigator>
      <last_name>Ma Angeles Goni Herranz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario De Santiago De Compostela Travesia Choupana S/N</name>
      <address>
        <city>Santiago de Compostela</city>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Beatriz Antelo Rodríguez</last_name>
      <phone>+34 981 950 549</phone>
      <email>beatriz.antelo@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Manuel Mateo Perez Encinas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan Carlos Hernández Boluda</last_name>
      <phone>+34 961 973 500</phone>
      <phone_ext>436697</phone_ext>
      <email>hernandez_jca@gva.es</email>
    </contact>
    <investigator>
      <last_name>Juan Carlos Hernández Boluda</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Western General Hospital</name>
      <address>
        <city>Edinburgh</city>
        <state>Scotland</state>
        <zip>EH4 2XU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andrea Stanton</last_name>
      <phone>(0131) 5372454</phone>
      <email>andrea.stanton@nhslothian.scot.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Ioannis Koutsavlis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital of Wales</name>
      <address>
        <city>Cardiff</city>
        <state>Wales</state>
        <zip>CF14 4XW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Snehal Akkaladevi</last_name>
      <phone>(44 29) 20745186</phone>
      <email>Snehal.Akkaladevi@wales.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Steven Knapper, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pilgrim Hospital</name>
      <address>
        <city>Boston</city>
        <zip>PE21 9QS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simon Archer</last_name>
      <phone>01205 445790</phone>
      <email>simon.archer@ulh.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Ciro Rinaldi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Haematology Trials Team</last_name>
      <phone>01223 216083</phone>
      <email>cctc@addenbrookes.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Anna Godfrey</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Imperial College Healthcare NHS Trust, Hammersmith Hospital</name>
      <address>
        <city>London</city>
        <zip>W12 0HS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Innes</last_name>
      <phone>02083834340</phone>
      <email>andrew.innes2@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Andrew Innes</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 20, 2020</study_first_submitted>
  <study_first_submitted_qc>October 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 26, 2020</study_first_posted>
  <last_update_submitted>October 25, 2021</last_update_submitted>
  <last_update_submitted_qc>October 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pelabresib</keyword>
  <keyword>Ruxolitinib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polycythemia Vera</mesh_term>
    <mesh_term>Primary Myelofibrosis</mesh_term>
    <mesh_term>Polycythemia</mesh_term>
    <mesh_term>Thrombocytosis</mesh_term>
    <mesh_term>Thrombocythemia, Essential</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

